國家衛生研究院 NHRI:Item 3990099045/14654

NHRI > National Institute of Infectious Diseases and Vaccinology > Ming-Hsi Huang > Periodical Articles > Item 3990099045/14654

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14654

Title:	Formulation of SARS-CoV-2 spike protein with CpG oligodeoxynucleotides and squalene nanoparticles modulates immunological aspects following intranasal delivery
Authors:	Ho, HM;Huang, CY;Yang, CH;Liu, SJ;Chen, HW;Yu, GY;Chen, JK;Chuang, TH;Huang, MH
Contributors:	National Institute of Infectious Diseases and Vaccinology;Institute of Biomedical Engineering and Nanomedicine;Immunology Research Center
Abstract:	Nasal spray vaccination is viewed as a promising strategy for inducing both mucosal and systemic protection against respiratory SARS-CoV-2 coronavirus. Toward this goal, a safe and efficacious mucosal adjuvant is necessary for the transportation of the antigen across the mucosal membrane and antigen recognition by the mucosal immune system to generate broad-spectrum immune responses. This study describes the immunological aspects of SARS-CoV-2 spike (S)-protein after being formulated with CpG oligodeoxynucleotides (ODNs) and squalene nanoparticles (termed PELC). Following intranasal delivery in mice, higher expression levels of major histocompatibility complex (MHC) class II and costimulatory molecules CD40 and CD86 on CD11c(+) cells were observed at the draining superficial cervical lymph nodes in the CpG-formulated S protein group compared with those vaccinated with S protein alone. Subsequently, the activated antigen-presenting cells downstream modulated the cytokine secretion profiles and expanded the cytotoxic T lymphocyte activity of S protein-restimulated splenocytes. Interestingly, the presence of PELC synergistically enhanced cell-mediated immunity and diminished individual differences in S protein-specific immunogenicity. Regarding humoral responses, the mice vaccinated with the PELC:CpG-formulated S protein promoted the production of S protein-specific IgG in serum samples and IgA in nasal and bronchoalveolar lavage fluids. These results indicate that PELC:CpG is a potential mucosal adjuvant that promotes mucosal/systemic immune responses and cell-mediated immunity, a feature that has implications for the development of a nasal spray vaccine against COVID-19.
Date:	2022-11-21
Relation:	Pharmaceutics. 2022 Nov 21;14(11):Article number 2539.
Link to:	http://dx.doi.org/10.3390/pharmaceutics14112539
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1999-4923&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000895707400001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85149504741
Appears in Collections:	[Ming-Hsi Huang] Periodical Articles [Guann-Yi Yu] Periodical Articles [Hsin-Wei Chen] Periodical Articles [Shih-Jen Liu] Periodical Articles [Jen-Kun Chen] Periodical Articles [Tsung-Hsien Chuang] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB36432730.pdf		2501Kb	Adobe PDF	137	View/Open

Loading...